$KSEZ
Kinetic Seas Inc.

2024 Q1 Form 10-Q Financial Statement

#000168316824003401 Filed on May 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023 Q1
Revenue $10.55K $0.00
YoY Change
Cost Of Revenue $7.841K $0.00
YoY Change
Gross Profit $2.713K $0.00
YoY Change
Gross Profit Margin 25.71%
Selling, General & Admin $92.21K $2.726K
YoY Change 3282.43% 101.93%
% of Gross Profit 3398.64%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $3.742K $0.00
YoY Change
% of Gross Profit 137.93%
Operating Expenses $197.5K $2.726K
YoY Change 7145.08% 101.93%
Operating Profit -$194.8K -$2.726K
YoY Change 7045.56% 101.93%
Interest Expense $4.550K $4.596K
YoY Change -1.0% 104.45%
% of Operating Profit
Other Income/Expense, Net -$4.550K -$4.596K
YoY Change -1.0% 104.45%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$199.3K -$7.322K
YoY Change 2622.45% 103.5%
Net Earnings / Revenue -1888.74%
Basic Earnings Per Share -$0.01 $0.00
Diluted Earnings Per Share -$0.01 $0.00
COMMON SHARES
Basic Shares Outstanding 29.15M shares 3.046M shares 140.8M shares
Diluted Shares Outstanding 29.15M shares 140.8M shares

Balance Sheet

Concept 2024 Q1 2023 Q4 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $1.708K $17.93K $13.36K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables $10.55K $0.00
Other Receivables
Total Short-Term Assets $12.26K $17.93K $13.36K
YoY Change -8.18% 1203.13%
LONG-TERM ASSETS
Property, Plant & Equipment $92.92K $13.14K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $92.92K $13.14K $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $12.26K $17.93K $13.36K
Total Long-Term Assets $92.92K $13.14K $0.00
Total Assets $105.2K $31.07K $13.36K
YoY Change 687.6% 2158.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $15.19K $0.00 $11.07K
YoY Change 37.19% -100.0%
Accrued Expenses $41.33K $33.49K $33.49K
YoY Change 23.42% 0.0%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $250.0K $226.6K $176.8K
YoY Change 41.4% 43.84%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $250.0K $226.6K $176.8K
Total Long-Term Liabilities
Total Liabilities
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$1.317M -$1.118M -$964.2K
YoY Change 36.61% 16.82%
Common Stock $316.00 $266.00 $1.408K
YoY Change -77.56% -81.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$144.9K -$195.5K -$163.5K
YoY Change
Total Liabilities & Shareholders Equity $105.2K $31.07K $13.36K
YoY Change 687.6% 2158.14%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023 Q1
OPERATING ACTIVITIES
Net Income -$199.3K -$7.322K
YoY Change 2622.45% 103.5%
Depreciation, Depletion And Amortization $3.742K $0.00
YoY Change
Cash From Operating Activities -$182.7K -$4.021K
YoY Change 4443.65%
INVESTING ACTIVITIES
Capital Expenditures $83.52K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$83.52K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $250.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $250.0K $16.00K
YoY Change 1462.5% -20.0%
NET CHANGE
Cash From Operating Activities -$182.7K -$4.021K
Cash From Investing Activities -$83.52K $0.00
Cash From Financing Activities $250.0K $16.00K
Net Change In Cash -$16.22K $11.98K
YoY Change -235.43% -40.11%
FREE CASH FLOW
Cash From Operating Activities -$182.7K -$4.021K
Capital Expenditures $83.52K $0.00
Free Cash Flow -$266.2K -$4.021K
YoY Change 6520.82%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Assets Current
AssetsCurrent
17931 usd
CY2023Q4 us-gaap Assets
Assets
31072 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2726 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
4596 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4596 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7322 usd
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29146000 shares
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1295 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4021 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
-0 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2023Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
16000 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
11979 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1376 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13355 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
12262 usd
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
92922 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13141 usd
CY2024Q1 us-gaap Assets
Assets
105184 usd
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
15188 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
0 usd
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
41327 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
33486 usd
CY2024Q1 us-gaap Interest Payable Current
InterestPayableCurrent
11519 usd
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
11098 usd
CY2024Q1 ECG Notes Payable Related Parties Current
NotesPayableRelatedPartiesCurrent
182000 usd
CY2023Q4 ECG Notes Payable Related Parties Current
NotesPayableRelatedPartiesCurrent
182000 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
250034 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
226584 usd
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 usd
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31646000 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31646000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26646000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26646000 shares
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
316 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
266 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1171970 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
922020 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1317136 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1117798 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-144850 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-195512 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
105184 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31072 usd
CY2024Q1 us-gaap Revenues
Revenues
10554 usd
CY2023Q1 us-gaap Revenues
Revenues
0 usd
CY2024Q1 us-gaap Cost Of Revenue
CostOfRevenue
7841 usd
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
0 usd
CY2024Q1 us-gaap Gross Profit
GrossProfit
2713 usd
CY2023Q1 us-gaap Gross Profit
GrossProfit
0 usd
CY2024Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
92205 usd
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
0 usd
CY2024Q1 us-gaap Professional Fees
ProfessionalFees
21994 usd
CY2023Q1 us-gaap Professional Fees
ProfessionalFees
2726 usd
CY2024Q1 us-gaap Labor And Related Expense
LaborAndRelatedExpense
64529 usd
CY2023Q1 us-gaap Labor And Related Expense
LaborAndRelatedExpense
0 usd
CY2024Q1 ECG Rent Expense
RentExpense
18773 usd
CY2023Q1 ECG Rent Expense
RentExpense
0 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
197501 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
2726 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-194788 usd
CY2024Q1 us-gaap Interest Expense
InterestExpense
4550 usd
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4550 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-199338 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29146000 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3046000 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3046000 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-156149 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7322 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-163471 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-195512 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
250000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-199338 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-144850 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-199338 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7322 usd
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3742 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
0 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
10554 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-0 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
15188 usd
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
8262 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
4596 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-182700 usd
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
83523 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-83523 usd
CY2024Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 usd
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
250000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
250000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-16223 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17931 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1708 usd
CY2024Q1 ECG Reduction Of Accrued Interest With Common Stock
ReductionOfAccruedInterestWithCommonStock
50000 usd
CY2023Q1 ECG Reduction Of Accrued Interest With Common Stock
ReductionOfAccruedInterestWithCommonStock
0 usd
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26646000 shares
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
250000 usd
CY2023Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
reverse split of 1 for 100
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_845_eus-gaap--UseOfEstimates_zUHRELVt37G6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration: underline">Use of Estimates</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of accrued liabilities and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to revenue recognition, valuation of accounts receivable and the allowance for doubtful accounts, inventories, and contingencies. The Company bases its estimates on historical experience, known or expected trends, and various other assumptions that are believed to be reasonable given the quality of information available as of the date of these financial statements. The results of these assumptions provide the basis for making estimates about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p>
CY2024Q1 us-gaap Cost Of Revenue
CostOfRevenue
7841 usd
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1708 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17931 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1317136 usd
CY2024Q1 ECG Working Capital
WorkingCapital
-237772 usd
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
41327 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
33486 usd
CY2024Q1 us-gaap Interest Expense
InterestExpense
4550 usd
CY2024Q1 ECG Notes Payable Related Parties Current
NotesPayableRelatedPartiesCurrent
182000 usd
CY2024Q1 us-gaap Interest Payable Current
InterestPayableCurrent
11519 usd
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31646000 shares
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001683168-24-003401-index-headers.html Edgar Link pending
0001683168-24-003401-index.html Edgar Link pending
0001683168-24-003401.txt Edgar Link pending
0001683168-24-003401-xbrl.zip Edgar Link pending
ecg-20240331.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
kinetic_ex3101.htm Edgar Link pending
kinetic_ex3201.htm Edgar Link pending
kinetic_i10q-033124.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ecg-20240331_def.xml Edgar Link unprocessable
ecg-20240331_lab.xml Edgar Link unprocessable
ecg-20240331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
kinetic_i10q-033124_htm.xml Edgar Link completed
ecg-20240331_cal.xml Edgar Link unprocessable